SCHEMBL6434041

SCHEMBL6434041

CCCCCCCCC=CC(=O)OCCC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.57
HCAR2 Q8TDS4 4/20 0.56
MAPT P10636 2/20 0.51
PPARG P37231 2/20 0.49
PPARA Q07869 2/20 0.49
FAAH O00519 2/20 0.47
GMNN O75496 1/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
POLB P06746 1/20 0.47
CYP2C9 P11712 1/20 0.47
ALOX15 P16050 1/20 0.47
APEX1 P27695 1/20 0.47
CYP2C19 P33261 1/20 0.47
RECQL P46063 1/20 0.47
BLM P54132 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
DUSP3 P51452 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9171083 1.00 ATM (0.57) ATMHCAR2MAPTPPARGPPARA
SCHEMBL8983014 1.00 ATM (0.57) ATMHCAR2MAPTPPARGPPARA
SCHEMBL15366563 1.00 ATM (0.57) ATMHCAR2MAPTPPARGPPARA
SCHEMBL15366566 1.00 ATM (0.57) ATMHCAR2MAPTPPARGPPARA
SCHEMBL6256088 1.00 ATM (0.57) ATMHCAR2MAPTPPARGPPARA
SCHEMBL9171086 1.00 ATM (0.57) ATMHCAR2MAPTPPARGPPARA
SCHEMBL28489018 0.98 ATM (0.59) ATMHCAR2MAPTPPARGPPARA
SCHEMBL22588816 0.98 ATM (0.59) ATMHCAR2MAPTPPARGPPARA
SCHEMBL14956745 0.94 ATM (0.59) ATMHCAR2MAPTPPARGPPARA
SCHEMBL12691676 0.94 ATM (0.59) ATMHCAR2MAPTPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043402-A1 Methods and formulations for counteracting infection of mucosa or skin LIPOMEDICA EHF. (IS) 2005-02-24 US disclosed
US-6596763-B1 Method for counteracting infections caused by bacteria, fungi or virus such as Herpes Simplex Virus in skin or mucosal membranes, in particular genital membranes, of a mammal. The method comprises topically administering to skin or mucous LIPOMEDICA EHF. (IS) 2003-07-22 US disclosed
EP-0941087-A1 TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS Thormar, Halldor (IS) 1999-09-15 EP disclosed
WO-1998020872-A1 TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS THORMAR HALLDOR (IS) 1998-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043402-A1 Methods and formulations for counteracting infection of mucosa or skin MGLL, GK, UGCG ATM 3505/4885HCAR2 1052/4885MAPT 4579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.